🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "major milestone" in the fight against superbug strains of the bacteria, according to researchers.

An International Challenge

The sexually transmitted infection are on the rise worldwide, with data suggesting over 82 million instances per year. Especially elevated rates are seen in Africa and nations within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. Across England, cases have hit a record high, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely step in the reality of rising global incidence, increasing antimicrobial resistance and the highly restricted available drugs presently on offer.”

Health officials are increasingly worried about the rise in drug-resistant strains. The WHO has designated it as a "high-priority threat". Recent surveillance showed that the effectiveness of primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Treatment Options Gain Clearance

One new antibiotic, marketed under the name Nuzolvence, was authorized by the American regulatory agency in December for combating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Researchers anticipate that specific application of this new drug will help delay the emergence of superbugs.

Gepotidacin, created by the pharmaceutical company GSK, gained clearance in concurrent days. This medication, which is employed against urinary tract infections, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin was the result of a innovative non-profit model for drug creation. The non-profit organisation GARDP partnered with the pharmaceutical company Innoviva to develop it.

“This approval marks a significant shift in the management of multidrug-resistant gonorrhoea, which previously has been evolving faster than antibiotic development.”

Research Study Results and Worldwide Availability

As per results detailed in a prominent scientific publication, zoliflodacin successfully treated more than 90% of uncomplicated infections. This places it at an comparable level with the current standard treatment, which involves an injection and a pill. The study included nearly 1,000 patients from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, GARDP has the rights to register and commercialise the drug in a wide range of low-income and middle-income countries.

Medical professionals treating patients have shared positive views. Having a one-pill regimen like this is hailed as a "critical tool" for public health efforts. This is considered vital to lessen the impact of the infection for individuals and to halt the transmission of highly drug-resistant gonorrhoea globally.